T Cell Interferon-gamma Release Assay (TIGRA) in Immunocompromised Individuals (TBNET-TIPS)
Prospective Head-to-head Comparison of the Two Commercially Available Approved TIGRA (QuantiFERON-TB Gold In-Tube and T.SPOT.TB) With the Established Mendel-Mantoux Skin-test in Immunocompromized Patients
Sponsor: Tuberculosis Network European Trialsgroup
A observational or N/A phase clinical study on Monitoring, Immunologic and Tuberculosis, this trial is completed. The trial is conducted by Tuberculosis Network European Trialsgroup and has accumulated 11 data snapshots since 2008. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Nov 2020 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Aug 2017 [monthly]
Completed NA
First recorded
Jun 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tuberculosis Network European Trialsgroup
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ankara, Turkey (Türkiye) , Barcelona, Spain , Borstel, Germany , Bucharest, Romania , Carnegie, Australia , Frankfurt, Germany , Freiburg im Breisgau, Germany , Geneva, Switzerland , Herlev, Denmark , Homburg, Germany and 9 more locations